Artificial intelligence (AI) holds the promise of transforming drug discovery. By harnessing large sets of chemical and biological data, AI can accurately predict the behavior and properties of small molecules. Thereby, they can accelerate the delivery of candidate compounds. One of the most powerful sources of data in hit generation is DNA-encoded library (DEL) screening. Both AI and DEL screening are transforming early phase drug discovery.
In this talk, the featured speakers will describe how DEL screening paired with AI can enhance the drug discovery process. By utilizing DEL screening data and other proprietary chemical data sources, AI can bring the power of accurate predictive models to drug hunters. The speakers will walk through case studies of AI’s application to de novo hit generation, DEL hit explosion, DEL building block reactivity prediction and prediction of key pharmacological properties. Further, they will discuss how these powerful capabilities can be integrated into a holistic, AI-accelerated process from screen to candidate.
Join this webinar to learn how the application of AI to existing technologies can improve and accelerate drug discovery.
Matt Clark, Chief Executive Officer, X-Chem
Matt is a world-recognized innovator and leader in the DNA-encoded library (DEL) field. He was part of X-Chem’s founding team and served as Vice President of Chemistry and Senior Vice President of Research prior to his appointment to the CEO position. Under his scientific leadership, the company developed from a niche chemical discovery platform to a world-leading drug discovery engine serving the biopharma industry. Before joining X-Chem, Matt was Director of Chemistry at GlaxoSmithKline, where he led the group responsible for design and synthesis of early-iteration DELs. He began his professional career at Praecis Pharmaceuticals, where he played a key role in the early development and implementation of technologies that would become the basis for DEL. Matt is a thought leader in the DEL space, with numerous patents and key DEL publications to his name. He received his BS in biochemistry from the University of California, San Diego, holds a PhD in chemistry from Cornell University and conducted postdoctoral studies at the Massachusetts Institute of Technology.Message Presenter
Noor Shaker, Senior Vice President and General Manager, X-Chem
Noor is a biotech entrepreneur and recognized healthcare innovator. Prior to Glamorous AI (acquired by X-Chem in October 2021), she was an Assistant Professor at Aalborg University. Noor is passionate about data and artificial intelligence (AI) and is on a mission to cure disease by pushing the boundaries of what is possible with AI. She has a record of achievements in AI, including numerous papers published in the field and its application to drug discovery. She also holds a number of AI patents. She sits on AI and diversity advisory boards for prestigious organizations and universities and is a recognized healthcare leader. She was one of the 2018 winners of Innovators Under 35 Europe from MIT Technology Review, and was named one of BBC’s 100 Women of 2019.Message Presenter
Who Should Attend?
- Scientists in drug discovery
- Executives in drug discovery
What You Will Learn
Attendees will learn:
- How artificial intelligence (AI) and DNA-encoded library (DEL) screening are transforming early phase drug discovery
- How this can impact all stages of discovery from screen to candidate
X-Chem is a leader in small molecule drug discovery services for pharmaceutical and biotech companies. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. As experts in medicinal chemistry, X-Chem can take those leads and progress them to clinical candidates with unmatched speed. Throughout the process, X-Chem’s advanced proprietary artificial intelligence (AI) technology accelerates all steps in the process. X-Chem also provides libraries, reagents and informatic tools to allow DEL operators to get the most of their DEL platform. X-Chem empowers its partners to effectively build drug pipelines from target to clinical candidate, enhanced with AI. For further information, please visit www.x-chemrx.com.